TD2 to Highlight Development of a Dual-Specific Inhibitor for Treatment of Primary Myelofibrosis at ASH Annual Meeting
SCOTTSDALE, ARIZONA, USA, December 5, 2023 /EINPresswire.com/ -- Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of preclinical results of RR-1752, a targeted inhibitor of ROCK/ …